Apple returns for another week as the top-performing Dow stock for the year to date even though shares dropped nearly 1.5% in another week of losses in U.S. equities markets.
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Pharmaceutical maker Merck beat adjusted earnings estimates but missed slightly on revenues when it reported Q3 results Thursday morning. Investors responded positively, however.
Paul Ausick These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices for worried investors to consider now.
24/7 Wall St. has put together a preview of Boeing, Intel, Verizon and the other Dow companies scheduled to report their quarterly results this week.
Apple shares dipped again last week, but the company managed to hold onto its rank as the top-performing Dow stock for the year to date. Shares are up nearly 30% in 2018.
Merck shares were up handily on Tuesday after the company announced a key update from the FDA on its Lynparza for the treatment of pancreatic cancer.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Tuesday included Adobe, Bank of America, Boston Scientific, Facebook, Las Vegas Sands, Merck, Tilray, TJX Companies and Valero Energy.
Apple survived a bloody week in the markets to return as the best-performing Dow Jones industrial stock for the year to date.
The top analyst upgrades, downgrades and initiations seen on Thursday included Abercrombie & Fitch, CME, Costco, DowDuPont, Gap, HCA, Herbalife, Merck, PayPal and Urban Outfitters.
The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the remainder of October.
Chris Lange These five well-known stocks may be laggards but they look like they have solid upside potential, and all can help add alpha to portfolios.
Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of October.
The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
